Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults with Hypertension : The National Health and Nutrition Examination Survey , 2001 to 2010

Background—The monitoring of national trends in hypertension treatment and control can provide important insight into the effectiveness of primary prevention efforts for cardiovascular disease. The objective of this study was to examine recent trends in antihypertensive medication use and its impact on blood pressure control among US adults with hypertension. Methods and Results—A total of 9320 hypertensive people aged 18 years from the National Health and Nutrition Examination Survey 2001 to 2010 were included in this study. The prevalence of antihypertensive medication use increased from 63.5% in 2001 to 2002 to 77.3% in 2009 to 2010 (Ptrend 0.01). Most notably, there was a large increase in the use of multiple antihypertensive agents (from 36.8% to 47.7%, Ptrend 0.01). Overall, the use of thiazide diuretics, -blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%, and 100%, respectively. In comparison with monotherapy, single-pill combinations and multiple-pill combinations were associated with 55% and 26% increased likelihoods of blood pressure control, respectively. By the 2009 to 2010 time period, 47% of all hypertensive people and 60% of treated hypertensive people had blood pressure controlled. However, higher treated but uncontrolled hypertension rates continued to persist among older Americans, non-Hispanic blacks, diabetic people, and those with chronic kidney disease. Also, Mexican Americans with hypertension were still less likely to take antihypertensive medication than non-Hispanic whites with hypertension. Conclusions—Antihypertensive medication use and blood pressure control among US adults with hypertension significantly increased over the past 10 years. Combination therapy regimens can facilitate achievement of blood pressure goals. (Circulation. 2012;126:2105-2114.)

[1]  C. McCulloch,et al.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. , 2005, Archives of internal medicine.

[2]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[3]  M. Woodward,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension in China: Data from the China National Nutrition and Health Survey 2002 , 2008, Circulation.

[4]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[5]  G. Parati,et al.  Visit-to-Visit Blood Pressure Variability, Carotid Atherosclerosis, and Cardiovascular Events in the European Lacidipine Study on Atherosclerosis , 2012, Circulation.

[6]  A. Rothberg.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .

[7]  Lynne Stokes.  Introduction to Variance Estimation , 2008 .

[8]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[9]  E. Peterson,et al.  Hypertension Control Among Patients Followed by Cardiologists , 2012, Circulation. Cardiovascular quality and outcomes.

[10]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[11]  Y. Ostchega,et al.  Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. , 2010, NCHS data brief.

[12]  B. Davis,et al.  Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). , 2002, Journal of clinical hypertension.

[13]  R. Stafford,et al.  Changes in Antihypertensive Prescribing During US Outpatient Visits for Uncomplicated Hypertension Between 1993 and 2004 , 2006, Hypertension.

[14]  G. Mancia,et al.  Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial , 2002, Circulation.

[15]  Hilary K. Wall,et al.  National Surveillance Definitions for Hypertension Prevalence and Control Among Adults , 2012, Circulation. Cardiovascular quality and outcomes.

[16]  E. O’Brien,et al.  Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension , 2010, The Lancet.

[17]  B. Egan,et al.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. , 2010, JAMA.

[18]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[19]  L. Vatten,et al.  Hypertensive Disorders in Pregnancy and Subsequently Measured Cardiovascular Risk Factors , 2009, Obstetrics and gynecology.

[20]  David Siegel,et al.  Trends in Antihypertensive Drug Use in the United States: Do the JNC V Recommendations Affect Prescribing? , 1997 .

[21]  Daniel W. Jones,et al.  Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.

[22]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[23]  J. Basile,et al.  The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy , 2006, Journal of Human Hypertension.

[24]  TuijaMännistö,et al.  Elevated Blood Pressure in Pregnancy and Subsequent Chronic Disease Risk , 2013 .

[25]  P. Whelton,et al.  Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. , 2000, Hypertension.

[26]  J. Bryant,et al.  Disease Control Priorities in Developing Countries , 1996 .

[27]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[28]  K. Reynolds,et al.  Global burden of hypertension: analysis of worldwide data , 2005, The Lancet.

[29]  D. Magid,et al.  A Pharmacist-Led, American Heart Association Heart360 Web-Enabled Home Blood Pressure Monitoring Program , 2013, Circulation. Cardiovascular quality and outcomes.

[30]  C. Dillon,et al.  Antihypertensive Medication Use Among US Adults With Hypertension , 2006, Circulation.

[31]  A. Mainous,et al.  Antihypertensive Prescribing Practices: Impact of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial , 2006, Journal of clinical hypertension.

[32]  Marco Valgimigli,et al.  Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.

[33]  S. Yusuf,et al.  Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) , 2011, Circulation.

[34]  Rationale for Combination Therapy in the Management of Hypertension , 2003, Journal of clinical hypertension.

[35]  C. Dillon,et al.  Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. , 2008, American journal of hypertension.

[36]  Orton,et al.  EFFECTS ON BLOOD PRESSURE OF REDUCED DIETARY SODIUM AND THE DIETARY APPROACHES TO STOP HYPERTENSION ( DASH ) DIET , 2000 .

[37]  P. Cosgrove,et al.  Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country: Findings From a Cluster-Randomized, Factorial-Controlled Trial , 2011, Circulation.

[38]  Daniel W. Jones,et al.  Effect of dietary protein supplementation on blood pressure: a randomized, controlled trial. , 2011, Circulation.

[39]  Jiang He,et al.  Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials , 2001, Hypertension.

[40]  S. Lewington.  Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[41]  J. Curb,et al.  To what extent do cardiovascular risk factor values measured in elderly men represent their midlife values measured 25 years earlier? A preliminary report and commentary from the Honolulu Heart Program. , 1994, American journal of epidemiology.

[42]  Blood Pressure Control and Pharmacotherapy Patterns in the United States Before and After the Release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) Guidelines , 2008, The Journal of the American Board of Family Medicine.

[43]  J. Selby,et al.  TRIALS STUDY PROTOCOL Open Access Study protocol: The Adherence and , 2022 .

[44]  W. Post,et al.  Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). , 2004, American journal of hypertension.

[45]  B. Sibai,et al.  Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. , 2002, American journal of obstetrics and gynecology.

[46]  Vicki L. Burt,et al.  Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010 , 2012, Circulation.

[47]  Benjamin S. Abella,et al.  Circ Cardiovasc Qual Outcomes , 2013 .

[48]  J. Selby,et al.  Improving Blood Pressure Control Through a Clinical Pharmacist Outreach Program in Patients With Diabetes Mellitus in 2 High-Performing Health Systems: The Adherence and Intensification of Medications Cluster Randomized, Controlled Pragmatic Trial , 2012, Circulation.

[49]  R. Victor,et al.  Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. , 2004, The American journal of medicine.

[50]  E. Hill.  With the WHO in China , 1948 .

[51]  W. Elliott.  US Trends in Prevalence, Awareness, Treatment, and Control of Hypertension, 1988-2008 , 2011 .

[52]  E. Ford.  Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States , 2011, Circulation.

[53]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[54]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. , 2003, JAMA.

[55]  A. Newman,et al.  Hypertension, White Matter Hyperintensities, and Concurrent Impairments in Mobility, Cognition, and Mood: The Cardiovascular Health Study , 2011, Circulation.

[56]  Karla Kerlikowske,et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials , 2000, The Lancet.

[57]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[58]  Jing Chen,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension in China , 2002, Hypertension.

[59]  Sudha Seshadri,et al.  Antecedent Blood Pressure and Risk of Cardiovascular Disease: The Framingham Heart Study , 2002, Circulation.

[60]  M. Burtscher.  Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[61]  D. Jacobs,et al.  Trends in Blood Pressure and Hypertension Detection, Treatment, and Control 1980 to 2009: The Minnesota Heart Survey , 2012, Circulation.

[62]  C. Furberg,et al.  Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States , 2006, Hypertension.

[63]  Alan D. Lopez,et al.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[64]  J. Coresh,et al.  Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). , 2001, Archives of internal medicine.

[65]  C. Nelson,et al.  Trends in Antihypertensive Drug Therapy of Ambulatory Patients by US Office-Based Physicians , 2000, Hypertension.

[66]  P. Rothwell,et al.  Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis , 2010, The Lancet.

[67]  Yan-jun Xu,et al.  Prevalence, Awareness, Treatment, and Control of Hypertension Among Residents in Guangdong Province, China, 2004 to 2007 , 2013, Circulation. Cardiovascular quality and outcomes.

[68]  J. Staessen,et al.  Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003–2004 Secondary Prevention Trials , 2005, Hypertension Research.

[69]  P. Serruys,et al.  Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium , 2010, European heart journal.

[70]  A. Rodgers,et al.  Global burden of blood-pressure-related disease, 2001 , 2008, The Lancet.

[71]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[72]  Rod Jackson,et al.  Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk , 2005, The Lancet.

[73]  J. Geleijnse,et al.  Dietary Protein and Blood Pressure: A Systematic Review , 2010, PloS one.

[74]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[75]  G. Mancia,et al.  When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal , 2009, Journal of hypertension.

[76]  N J Wald,et al.  Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials , 2003, BMJ : British Medical Journal.

[77]  P. Whelton,et al.  Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidel , 2009, Hypertension.

[78]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[79]  Ronald E. Jones,et al.  Blood Pressure Control Among US Veterans: A Large Multiyear Analysis of Blood Pressure Data From the Veterans Administration Health Data Repository , 2012, Circulation.

[80]  Pascal Vranckx,et al.  Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.

[81]  A. Dyer,et al.  Impact of Blood Pressure and Blood Pressure Change During Middle Age on the Remaining Lifetime Risk for Cardiovascular Disease: The Cardiovascular Lifetime Risk Pooling Project , 2012, Circulation.

[82]  D. Petitti,et al.  Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. , 2005, American journal of hypertension.

[83]  Heather M. Tavel,et al.  Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients , 2012, Circulation.

[84]  W. Elliott.  Community-Based Interventions to Promote Blood Pressure Control in a Developing Country: A Cluster Randomized Trial , 2010 .

[85]  V. Andros,et al.  Blood Pressure Goal Attainment According to JNC 7 Guidelines and Utilization of Antihypertensive Drug Therapy in MCO Patients With Type 1 or Type 2 Diabetes , 2006, Journal of managed care pharmacy : JMCP.

[86]  L. Bautista.  Predictors of persistence with antihypertensive therapy: results from the NHANES. , 2008, American journal of hypertension.